Neoplasma,
Journal Year:
2022,
Volume and Issue:
69(06), P. 1359 - 1372
Published: Jan. 1, 2022
Liver
cancer
is
one
of
the
most
common
tumors
with
a
high
malignant
degree
in
world.
Its
diagnosis
and
treatment
are
very
difficult
limited.
More
novel
powerful
DAT
strategies
urgently
needed
to
break
this
situation.
An
increasing
number
studies
have
shown
that
microRNAs
(miRNAs)
could
be
used
not
only
as
biomarkers
for
prognosis
hepatocellular
carcinoma
(HCC)
but
also
important
targets
molecular
targeted
therapy.
However,
role
miR-550a-5p
HCC
its
specific
mechanism
remain
unclear.
Here
we
proposed
verified
hypothesis
regulate
progression
was
positively
associated
poor
prognosis.
We
found
decreased
would
inhibit
proliferation
migration
cell
lines
(HCs)
by
performing
relevant
assays.
Interestingly,
knocking
down
GNE
reverse
above
effect
on
HCs.
Meanwhile,
western
blot
results
showed
Wnt/β-catenin
signaling
pathway
at
least
partly
involved
regulation
miR-550a-5p.
In
addition,
suppress
growth
vivo
via
xenograft
tumor
model
assay.
All
all,
draw
conclusion
miR-550a-5p/GNE
axis
functioned
an
promoting
pathway.
Biomolecules,
Journal Year:
2023,
Volume and Issue:
13(3), P. 560 - 560
Published: March 20, 2023
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
currently
the
most
common
cause
of
chronic
worldwide.
Early
identification
and
prompt
treatment
are
critical
to
optimize
patient
management
improve
long-term
prognosis.
Long
non-coding
RNA
(lncRNA)
circular
(circRNA)
recently
emerging
RNAs,
highly
stable
easily
detected
in
circulation,
representing
a
promising
non-invasive
approach
for
predicting
NAFLD.
A
literature
search
Pubmed,
Embase,
Web
Science,
Cochrane
Library
databases
was
performed
36
eligible
studies
were
retrieved,
including
18
on
NAFLD,
13
nonalcoholic
steatohepatitis
(NASH),
11
fibrosis
and/or
cirrhosis.
Dynamic
changes
lncRNA
expression
associated
with
occurrence
progression
among
which
NEAT1,
MEG3,
MALAT1
exhibited
great
potential
as
biomarkers
Moreover,
mitochondria-located
circRNA
SCAR
can
drive
metaflammation
its
inhibition
might
be
therapeutic
target
NASH.
In
this
systematic
review,
we
highlight
lncRNA/circRNA
early
diagnosis
assessment
To
further
verify
their
clinical
value,
large-cohort
incorporating
both
tissue
blood
should
conducted.
Additionally,
detailed
functional
mechanisms
will
essential
elucidating
roles
diagnosing
treating
NASH,
fibrosis.
Non-coding RNA Research,
Journal Year:
2023,
Volume and Issue:
9(1), P. 24 - 32
Published: Oct. 24, 2023
Hepatocellular
carcinoma
(HCC)
is
primary
liver
cancer,
frequently
diagnosed
at
advanced
stages
with
limited
therapeutic
options.
MicroRNAs
(miRNAs)
regulate
target
gene
expression
and
through
inhibitory
competitive
binding
of
miRNA
influence
cellular
processes
including
carcinogenesis.
Extensive
evidence
proved
that
certain
miRNA's
are
specifically
expressed
in
neoplastic
tissues
HCC
patients
confirmed
as
important
factors
can
participate
the
regulation
key
signalling
pathways
cancer
cells.
As
such,
miRNAs
have
a
great
potential
clinical
diagnosis
treatment
improve
limitations
standard
treatment.
Long
non-coding
RNAs
(lncRNAs)
critical
role
development
progression
HCC.
HCC-related
lncRNAs
been
demonstrated
to
exhibit
abnormal
contribute
transformation
process
(such
proliferation,
apoptosis,
accelerated
vascular
formation,
gain
invasive
potential)
their
interaction
DNA,
RNA,
or
proteins.
LncRNAs
bind
mRNAs
release
mRNA
enable
its
translation.
These
lncRNA-miRNA
networks
cell
so
invasion,
metastasis,
angiogenesis,
epithelial-mesenchymal
transition
(EMT),
drug
resistance,
autophagy.
In
this
narrative
review,
we
focus
on
lncRNA
tumor
tissue
current
tools,
biomarkers
targets
unravelled
recent
years.
Frontiers in Oncology,
Journal Year:
2025,
Volume and Issue:
15
Published: March 10, 2025
Non-coding
RNAs
(ncRNAs)
have
a
significant
role
in
gene
regulation,
especially
cancer
and
inflammatory
diseases.
ncRNAs,
such
as
microRNA,
long
non-coding
RNAs,
circular
alter
the
transcriptional,
post-transcriptional,
epigenetic
expression
levels.
These
molecules
act
biomarkers
possible
therapeutic
targets
because
aberrant
ncRNA
has
been
directly
connected
to
tumor
progression,
metastasis,
response
therapy
research.
ncRNAs’
interactions
with
multiple
cellular
pathways,
including
MAPK,
Wnt,
PI3K/AKT/mTOR,
impact
processes
like
proliferation,
apoptosis,
immune
responses.
The
potential
of
RNA-based
therapeutics,
anti-microRNA
microRNA
mimics,
restore
normal
is
being
actively
studied.
Additionally,
tissue-specific
patterns
ncRNAs
offer
unique
opportunities
for
targeted
therapy.
Specificity,
stability,
responses
are
obstacles
use
ncRNAs;
however,
novel
strategies,
modified
oligonucleotides
delivery
systems,
developed.
profiling
may
result
more
individualized
successful
treatments
precision
medicine
advances,
improving
patient
outcomes
creating
early
diagnosis
monitoring
opportunities.
current
review
aims
investigate
roles
diseases,
focusing
on
their
mechanisms
regulation
implications
non-invasive
diagnostics
therapies.
A
comprehensive
literature
was
conducted
using
PubMed
Google
Scholar,
research
published
between
2014
2025.
Studies
were
selected
based
rigorous
inclusion
criteria,
peer-reviewed
status
relevance
Non-English,
non-peer-reviewed,
inconclusive
studies
excluded.
This
approach
ensures
that
findings
presented
high-quality
relevant
sources.
Pharmacological Research,
Journal Year:
2023,
Volume and Issue:
189, P. 106674 - 106674
Published: Jan. 23, 2023
Liver
cancer
is
one
of
the
most
common
malignancies,
with
severe
morbidity
and
mortality.
While
considerable
progress
has
been
made
in
liver
treatment,
5-year
overall
survival
(OS)
patients
not
improved
significantly.
Reasons
include
inadequate
capability
early
screening
diagnosis,
a
high
incidence
recurrence
metastasis,
degree
tumor
heterogeneity,
an
immunosuppressive
microenvironment.
Therefore,
identification
validation
specific
robust
biomarkers
are
major
importance
for
screening,
timely
accurate
prognosis,
prevention
progression.
In
this
review,
we
highlight
some
latest
research
potential
applications
biomarkers,
describing
hotspots
prospective
directions
biomarker
discovery.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(2), P. 1258 - 1258
Published: Jan. 19, 2024
Hepatocellular
carcinoma
(HCC)
presents
a
significant
global
health
challenge
due
to
limited
early
detection
methods,
primarily
relying
on
conventional
approaches
like
imaging
and
alpha-fetoprotein
(AFP).
Although
non-coding
RNAs
(ncRNAs)
show
promise
as
potential
biomarkers
in
HCC,
their
true
utility
remains
uncertain.
We
conducted
comprehensive
review
of
76
articles,
analyzing
88
circulating
lncRNAs
6426
HCC
patients.
However,
the
lack
standardized
workflow
protocol
has
hampered
holistic
comparisons
across
literature.
Consequently,
we
herein
confined
our
meta-analysis
only
subset
these
lncRNAs.
The
combined
analysis
serum
highly
upregulated
liver
cancer
(HULC)
gene
expression
with
homeobox
transcript
antisense
intergenic
RNA
(HOTAIR)
urothelial
carcinoma-associated
1
(UCA1)
demonstrated
markedly
enhanced
sensitivity
specificity
diagnostic
capability
compared
traditional
or
other
ncRNAs.
These
findings
could
have
substantial
implications
for
diagnosis
tailored
treatment
HCC.
Non-coding RNA Research,
Journal Year:
2024,
Volume and Issue:
9(4), P. 1315 - 1323
Published: July 1, 2024
This
review
article
studies
the
complex
field
of
noncoding
RNAs
(ncRNAs)
in
cancer
biology,
focusing
on
their
potential
use
as
biomarkers
and
therapeutic
targets.
NcRNAs
include
circular
(circRNAs),
long
(lncRNAs),
microRNAs
(miRNAs).
We
discuss
how
ncRNAs
affect
gene
expression
cancerous
cells,
spread
cancer,
metastasis.
The
illustrates
pathways
through
which
can
oncogenesis,
tumor
suppression,
resistance.
It
also
assesses
clinical
uses
non-coding
(ncRNAs),
including
utility
diagnosis,
prognosis.
Besides,
for
personalized
therapy
is
documented.
Finally,
it
concluded
that
understanding
role
ncRNA
importance
regarding
carcinogenesis,
therapy.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(4), P. 2414 - 2414
Published: Feb. 19, 2024
Ultrasound
screening
for
hepatocellular
carcinoma
(HCC)
in
patients
with
liver
cirrhosis
has
a
poor
sensitivity
small
tumors.
Circulating
microRNAs
(miRNAs)
have
been
explored
as
HCC
biomarkers,
but
results
are
diverging.
Here,
we
evaluate
if
miRNAs
up-regulated
tissue
can
be
detected
plasma
and
used
biomarkers
HCC.
In
this
cross-sectional
study,
plasma,
surrounding
non-tumorous
were
collected
from
resections.
Tissue
identified
quantitated
by
RNA-sequencing
analysis,
the
fold-changes
between
calculated.
The
HCCs
then
re-analyzed
same
patients,
highest
levels
subsequently
measured
an
independent
cohort
of
or
tissues
84
resected
197
differentially
expressed
miRNAs,
40
which
had
raw
count
above
200
analyzed
cohort.
Thirty-one
selected
further
analysis
cirrhosis.
Of
these,
eleven
significantly
increased
compared
to
patients.
Only
miR-93-5p
miR-151a-3p
associated
HCC,
AUC
0.662.
comparison,
alpha-fetoprotein
des-gamma-carboxy
prothrombin
yielded
0.816,
0.832
added.
When
including
sex
age,
addition
did
not
improve
(from
0.910
0.911).
conclusion,
micro-RNAs
detectable
performance
